Stock listing

Euronext:ALVIO Valerio Therapeutics Action

Home listing (Euronext) of Valerio Therapeutics

Follow Valerio Therapeutics into a list and get an email when it puts out news.

Share price · EURONEXT:ALVIO

€0.401 EUR +0.006 (+1.5%)

Close on Oct 16, 2026

Valerio Therapeutics logo
Ticker
Euronext:ALVIO
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
Euronext
Currency
EUR

What changed lately

Latest news

Valerio Therapeutics Completes Acquisition of Etherna Immunotherapies, Building an Integrated Targeted RNA Platform to Accelerate Progress Toward the Clinic

Oct 12, 2026

Valerio Therapeutics Provides an Update on Its Business and Presents Its Financial Results for the First Half of 2026

Oct 7, 2026

Valerio Therapeutics Announces Signing of Definitive Agreements for the Acquisition of Etherna Immunotherapies, Building a Leading Platform in Targeted RNA, and €40.25 Million PIPE Financing From New and Existing Investors

Aug 24, 2026

Valerio Therapeutics and Etherna Immunotherapies Progress Towards Finalisation of Transaction Documentation Regarding the Contemplated Acquisition

Aug 17, 2026

Valerio Therapeutics Announces Development Collaboration with Abivax and Provides Pipeline Update

Jul 16, 2026

Valerio Therapeutics Announces Binding Offer for the Proposed Acquisition of Etherna Immunotherapies, Creating a Global Leader in Targeted RNA Medicines

Jul 1, 2026

Valerio Therapeutics Appoints Gilles Besin as Chief Executive Officer and Announces Results of its Annual General Meeting

Jun 16, 2026

Valerio Therapeutics Announces Binding Term-Sheet for Collaboration and Exclusive License With Seed-Stage Biotech Company

May 18, 2026

Valerio Therapeutics Announces the Launch of InVimmune, a New Company Dedicated to Developing Differentiated in Vivo Cell Therapy Approaches

May 4, 2026

Valerio Therapeutics Publishes Its 2025 Annual Results and Annual Financial Report, and Confirms the Strategic Transformation of Its Operating Model

Apr 29, 2026

All Valerio Therapeutics news

Financings

  • Private placement of new ordinary shares

    Aug 24, 2026 · US$46.96M

    Announced: €40.25M · €0.59 a share · Van Lanschot Kempen NV

    Dealers: Van Lanschot Kempen NV (lead)

    Buyers: Artal International SCA (€18.0 million); Financière de la Montagne (€7.0 million); Saint James Luxembourg (€1.0 million)

    Insiders: Board-represented shareholders Artal International SCA (€18.0 million) and Financière de la Montagne (€7.0 million) subscribed and did not vote on the Financing

    Use of proceeds: Fund cash consideration for Etherna acquisition, advance VTX-001/002/003 pipeline, integrate Etherna and scale manufacturing, working capital

    Announced Aug 24, 2026

Read by 6ix AI from the company's releases

Decks

Valerio Therapeutics on 6ix

Sector
Health care
Industry
Biotechnology
News releases
24 in the last 12 months · 28 in all · newest Oct 12, 2026 · oldest 2025
Decks
3 decks · latest July 2026

Where Valerio Therapeutics is listed

ListingExchangeCountryCurrency
Euronext:ALVIO · Home listing · This pageEuronextFranceEUR
LS Exchange:A0HMXALS ExchangeGermanyEUR
Lang & Schwarz:A0HMXALang & SchwarzGermanyEUR
LSE:0NWKLSEUnited KingdomEUR
Munich:C4XMunichGermanyEUR
gettex:C4XgettexGermanyEUR
Frankfurt:C4XFrankfurtGermanyEUR
Stuttgart:C4XStuttgartGermanyEUR
Turquoise:ALVIOPTurquoiseUnited KingdomEUR

Log in to ask 6ix AI your own questions about Valerio Therapeutics.